ArticleMolecules (Basel, Switzerland)2026
Linear Residual Network Modeling for Anti-HIV-1 Activity Prediction and Docking-Validated Design of Biphenyl-DAPY-Based NNRTIs.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To predict the anti-HIV-1 activity of biphenyl-DAPY-based non-nucleoside reverse transcriptase inhibitors (NNRTIs), a quantitative structure-activity relationship (QSAR) analysis was conducted. Using the heuristic method (HM) for descriptor selection, four predictive models were established: support vector regression (SVR), kernel ridge regression, linear mixed-kernel SVR, and Linear Residual Network (LRNet). Rigorous validations, including leave-one-out cross-validation, fivefold cross-validation, and Y-randomization tests, confirmed their reliability. The LRNet model exhibited the best performance, achieving an average training set R2 of 0.8838±0.0090 and an average test set R2 of 0.9026±0.0187 over 50 random train-test splits, with Q5-fold2 and QLOO2 being 0.8533 and 0.8541, respectively. To further verify the robustness and generalizability of LRNet, independent validation was performed using an external dataset, where LRNet also achieved better generalization performance. The HM and LRNet models were employed to guide the design of novel compounds. Their favorable binding modes with the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.